Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to assets ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO ASSETS RATIO
N/A
Braveheart Bio, Inc.
Market Cap
$1.40B
Debt to Assets Ratio
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.40B | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 0.01% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | 0.12% |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 0.48% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 0.85% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | 0.95% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | 0.03% |
| Certara, Inc. (CERT)vs › | $1.44B | 0.21% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 0.02% |
| Omeros Corporation (OMER)vs › | $1.34B | 0.29% |
Debt/Assets
N/A
Debt/Equity
N/A
Current Ratio
N/A
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
